Clinical Trial Update: A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]

View source ↗

Summary

This ClinicalTrials.gov entry notes a Phase 2/3 study comparing oral azacitidine plus best supportive care versus placebo plus best supportive care in IPSS-R lo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Oral azacitidine (Onureg) (azacitidine)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myelodysplastic Syndromes | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING